SynthesisEndocrine2026
Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLung carcinoids (LCs) account for up to 25% of diagnosed NETs. Unlike gastroenteropancreatic NETs, LCs are more frequently associated with bone metastases (BMs), posing significant challenges due to their lower responsiveness to systemic treatments and the limited data on bone-modifying agents' efficacy in this setting.
methodsA systematic review on patients with BMs by LCs has been performed to assess the incidence of bone involvement, the clinical presentation and the current approach for both diagnosis and management.
resultsFrom the 61 selected articles, the incidence of BMs in LC patients was 17.2%, with a M/F ratio of 1.6. BMs were mostly symptomatic at diagnosis, while the 39% were detected only by imaging. Vertebrae were the most common site. Osteoblastic BMs were predominant BMs, while osteolitic BMs were more common in males. According on available data on nuclear medicine imaging, bone scintigraphy was positive in all cases. The most common treatments seemed to be radiotherapy and PRRT, while only two papers reported the effects of anti-resorptive agents in this setting. The median survival rate was 48,32 months, 24.9 months from the BMs detection.
conclusionThis systematic review focus on BMs in LCs, highlighting the challenges of diagnosis and therapy. First, our findings confirm the worse prognosis of LC patients with BMs vs. those without, pointing out the importance of the involvement of other specialists in managing these peculiar cases. Second, the need to evaluate the adequate techniques (including nuclear medicine) and timing of follow-up for these patients.
Indexed as
Identifiers
42714696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.